Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis Urothelial Carcinoma
- Locally Advanced Ureter Urothelial Carcinoma
- Locally Advanced Urethral Urothelial Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis Urothelial Carcinoma
- Metastatic Ureter Urothelial Carcinoma
- Metastatic Urethral Urothelial Carcinoma
- Recurrent Bladder Urothelial Carcinoma
- Recurrent Renal Pelvis Urothelial Carcinoma
- Recurrent Ureter Urothelial Carcinoma
- Recurrent Urethral Urothelial Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Renal Pelvis Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Unresectable Bladder Urothelial Carcinoma
- Unresectable Renal Pelvis Urothelial Carcinoma
- Unresectable Ureter Urothelial Carcinoma
- Unresectable Urethral Urothelial Carcinoma
Interventions
- DRUG: Atezolizumab
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography with Contrast
- DRUG: Eribulin Mesylate
Sponsor
National Cancer Institute (NCI)